Firebrick Pharma (ASX:FRE) Interest Received : A$0.03 Mil (TTM As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Firebrick Pharma Interest Received?

Firebrick Pharma's Interest Received for the six months ended in Dec. 2023 was A$0.01 Mil.

Firebrick Pharma's Interest Received for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.03 Mil.

Firebrick Pharma Interest Received Historical Data

The historical data trend for Firebrick Pharma's Interest Received can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Firebrick Pharma Interest Received Chart

Firebrick Pharma Annual Data

Trend

Jun21

Jun22

Jun23

Interest Received

0.04

Firebrick Pharma Semi-Annual Data
	Jun22	Dec22	Jun23	Dec23
Interest Received	-	0.02	0.02	0.01

Firebrick Pharma Interest Received Calculation

A company's cash flow from operations for a time period can be determined using either the direct or indirect method. The indirect method modifies the operating section from accrual accounting to a cash basis by taking the net income generated in a period and adding or subtracting changes in the asset and liability accounts to determine the implied cash flow. However, the direct method uses actual cash inflows and outflows from the company's operations directly. Interest Received represents interest received by the company in the direct cash flow method.

Interest Received for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.03 Mil.

Firebrick Pharma Interest Received Related Terms

Thank you for viewing the detailed overview of Firebrick Pharma's Interest Received provided by GuruFocus.com. Please click on the following links to see related term pages.

Firebrick Pharma (ASX:FRE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Firebrick Pharma Ltd (ASX:FRE) » Definitions » Interest Received

Comparable Companies

Traded in Other Exchanges

N/A

Address

440 Collins Street, Level 10, Melbourne, VIC, AUS, 3000

Website

https://www.firebrickpharma.com

Firebrick Pharma Ltd is an Australian pharmaceutical developer. It is engaged in the development and commercialization of Nasodine, a broad-spectrum anti-viral spray, designed to be an effective treatment and prevention of respiratory viral infections such as the common cold.

Firebrick Pharma (ASX:FRE) Headlines

No Headlines